NANOKINE

NANOKINE

NANOKINE

NANOKINE

NANOKINE

NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC.

Address:
Lot E2a-1, E2a-2 Saigon Hitech Park, Long Thanh My Ward, Thu Duc City, Ho Chi Minh City, VIETNAM
Lot I-5C Saigon Hitech Park, Tang Nhon Phu A Ward, Thu Duc City, Ho Chi Minh City, VIETNAM

Tel: (+84) 28 7108 9688

Fax: (+84) 283 730 9963

Email: info@nanogenpharma.com

NANOKINE

Home Products NANOKINE

NANOKINE

COMPOSITION
Each glass vial of 1 mL contains:
rHu EPO   2000 IU, 4000 IU, 10000 IU 
Each prefilled syringe of 0.5 mL contains: 
rHu EPO  2000 IU, 4000 IU
Each prefilled syringe of 1 mL contains: 
rHu EPO  10000 IU
DESCRIPTION
NANOKINE is produced from raw, high purity materials erythropoietin (EPO). The EPO is produced by recombinant DNA techniques on ovarian cell lines marsupial cheeks of China. The recombinant human erythropoietin and natural eryth ropoietin are shown to identically function in vivo. It stimu lates the production of red blood cells in bone marrow. 
Pharmacotherapeutic group : Hematopoietic agents
INDICATION
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients : 
  • On haemodialysis and on peritoneal dialysis. 
  • With renal insufficiency not yet undergoing dialysis. 
  • On chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the beginning stage of chemotherapy).
  • Increasing the yield of autologous blood from patients in a predonation programme.
  • Reducing exposure to allogeneic blood transfusions in adult non-iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications.
CONTRAINDICATION
NANOKINE should NOT be used for patients : 
  • Have uncontrolled hypertension.
  • Develop pure red cell aplasia (PRCA) following treatment with erythropoietin. 
  • Hypersensitivity to the active substance or to any of the excipients. 
  • Have surgery and cannot receive adequate antithrombotic prophylaxis for any reason.
  • Have autologous blood predonation programmes 
  • Are scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation. 
  • Suffer severe coronary, peripheral arterial, carotid artery disease or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
STORAGE, SHELF LIFE, PACKING UNITS
Storage: 
At 2oC - 8oC. Do not freeze. Protect from light.
Shelf life:  
24 months from manufacturing date.
Packing units: 
Box of 01 vial of solution for injection NANOKINE 2000 IU , 4000 IU , 10000 IU (1 mL) 
Box of 01 prefilled syringe of solution for injection 
NANOKINE 2000 IU  (0.5 mL) , 4000 IU  (0.5 mL), 10000 IU (1 mL)

Related products

Current product

FICOCYTE

Current product

PEGCYTE

Current product

PEGNANO

Current product

FERONSURE